Search

Rocket Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

3.52 0.57

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.49

Максимум

3.54

Ключови измерители

By Trading Economics

Приходи

171M

123M

EPS

-0.15

Служители

202

EBITDA

182M

137M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+218.23% upside

Дивиденти

By Acuity

Следващи печалби

4.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-24M

373M

Предишно отваряне

2.95

Предишно затваряне

3.52

Настроения в новините

By Acuity

48%

52%

140 / 340 Класиране в Healthcare

Rocket Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.08.2026 г., 19:51 ч. UTC

Correlated Moves

Rocket Pharmaceuticals Inc is rising during Friday's session, supported by strength in the biotechnology sector. The stock remains above its 20-day moving average.

20.08.2026 г., 20:06 ч. UTC

Correlated Moves

Rocket Pharmaceuticals Inc is lower today, reflecting broader pressures in the biotechnology sector. The overall market is also trending downwards.

19.08.2026 г., 20:02 ч. UTC

Correlated Moves

Rocket Pharmaceuticals Inc shares are sharply higher today, reflecting strong momentum amid notable gains in biotechnology stocks and positive sector dynamics.

18.08.2026 г., 19:46 ч. UTC

Rocket Pharmaceuticals shares are lower today, reflecting a decline since Monday. Broader market trends and rising Treasury yields may be influencing investor sentiment.

17.08.2026 г., 23:46 ч. UTC

Rocket Pharmaceuticals Inc shares are higher in after-market trading, reflecting positive performance despite broader market pressures and no specific company news identified.

14.08.2026 г., 22:01 ч. UTC

Rocket Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified. Broader market concerns may be influencing the decline.

13.08.2026 г., 19:56 ч. UTC

Rocket Pharmaceuticals Inc shares are lower today, continuing a recent downward trend amid rising U.S. unemployment claims, with no specific company news identified.

12.08.2026 г., 19:16 ч. UTC

Rocket Pharmaceuticals Inc shares are lower today, with no specific news driving the decline. Earlier, the stock reached a session high before falling.

11.08.2026 г., 20:02 ч. UTC

News

Rocket Pharmaceuticals shares are lower after Wedbush cut its price target to $15, reflecting concerns over mixed second-quarter earnings results.

10.08.2026 г., 23:26 ч. UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

8.08.2026 г., 00:01 ч. UTC

Rocket Pharmaceuticals Inc. shares are higher in after-market trading, advancing modestly since Friday's close and remaining above its 20-day moving average.

7.08.2026 г., 23:01 ч. UTC

Rocket Pharmaceuticals Inc. shares have shown little change in after-market trading, remaining within a narrow band since Friday's close.

6.08.2026 г., 23:06 ч. UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, remaining above its 20-day moving average amid no specific news to explain the movement.

5.08.2026 г., 20:02 ч. UTC

News

Rocket Pharmaceuticals is rising Wednesday, driven by a strong Biotechnology sub-sector. The stock remains above its 20-day moving average during the session.

4.08.2026 г., 19:26 ч. UTC

News
Event

Rocket Pharmaceuticals shares rise as Wedbush maintains Outperform rating with a $16 price target. The company also reported promising safety results in its Phase 2 trial.

3.08.2026 г., 22:01 ч. UTC

Event

Rocket Pharmaceuticals shares are lower in after-market trading despite a positive clinical safety update on its Phase 2 trial for RP-A501.

31.07.2026 г., 22:01 ч. UTC

Rocket Pharmaceuticals shares declined in after-hours trading, continuing a downward trend since Friday's close. The stock remains below its 20-day moving average.

30.07.2026 г., 21:51 ч. UTC

Rocket Pharmaceuticals is lower in after-market hours, reflecting declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

29.07.2026 г., 20:52 ч. UTC

Rocket Pharmaceuticals shares are lower in after-market hours amid a broader market decline driven by rising crude oil prices and geopolitical tensions.

28.07.2026 г., 19:22 ч. UTC

Rocket Pharmaceuticals Inc is trading lower today, reflecting broader market trends. The stock remains below its 20-day moving average and near its one-month trading range low.

27.07.2026 г., 16:16 ч. UTC

Rocket Pharmaceuticals is trading higher today, recovering from an earlier dip. Broader market volatility follows a notable decline in oil prices amid geopolitical developments.

24.07.2026 г., 19:06 ч. UTC

Rocket Pharmaceuticals is trading lower, extending a five-session decline. Broader market pressures and falling crude oil prices are influencing investor sentiment.

22.07.2026 г., 20:06 ч. UTC

Rocket Pharmaceuticals shares are lower, marking four consecutive sessions of declines. The stock has closed below its 20-day moving average.

20.07.2026 г., 19:46 ч. UTC

News

Rocket Pharmaceuticals shares are higher today amid mixed analyst sentiments, with Wall Street Zen downgrading to "sell" and Chardan Capital maintaining a "buy" rating.

Сравнение с други в отрасъла

Ценова промяна

Rocket Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

218.23% нагоре

12-месечна прогноза

Среден 11.17 USD  218.23%

Висок 15 USD

Нисък 5 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Rocket Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

8 ratings

5

Купи

3

Задържане

0

Продай

Настроение

By Acuity

140 / 340 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
help-icon Live chat